EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

High CA125 levels as a red flag for ATTR cardiac amyloidosis

Belén Peiró-Aventín iD, Enrique Santas, María Ruiz-Cueto, Nerea Mora-Ayestarán, Ana Briceño, Clara Badia, Daniel de Castro, Rafael de la Espriella iD, Basilio Angulo-Lara, Ana Espinoza, Jorge De La Fuente García, Mikel Maeztu Rada und 6 weitere

ESC Heart Failure · 04.07.2026 · 13 (4)

DOI: 10.1093/eschf/xvag199 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 22.07.2026. Verfasst von Belén Peiró-Aventín und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain. Hauptthemen laut MEDLINE: CA-125 Antigen, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Regional Development Fund/European Social Fund, Fundacion Eugenio Rodriguez Pascual.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Recognition of transthyretin cardiac amyloidosis (ATTR-CA) remains challenging. In heart failure, plasmatic carbohydrate antigen 125 (CA125) is an established biomarker, reflecting inflammation and volume overload, common issues in ATTR-CA. Our aim was to evaluate the potential utility of CA125 as a ‘rule-in’ biomarker for suspected ATTR-CA. Methods and Results This is a retrospective, multicentre, case–control study that included 626 consecutive ambulatory patients (median age 79 years, 74.8% male) from three tertiary centres. All individuals underwent 99mTc-DPD scintigraphy for suspected cardiac amyloidosis and had a CA125 determination available at the time of the evaluation. Following diagnostic workup, 451 (72%) patients were diagnosed with ATTR-CA, while 175 (28%) were ruled out for the disease. Patients with ATTR-CA showed a non-significant trend towards higher CA125 levels (16.2 [10.2–29.7] vs 14 [8–26.3] U/mL, P = .065). A CA125 cut-off of 40 U/mL yielded a positive predictive value of 81.7% (95% confidence interval: 78.6%–84.7%). In a multivariate logistic regression model, CA125 was an independent predictor for the diagnosis of ATTR-CA (odds ratio 2.109; 95% confidence interval: 1.197–3.717; P = .01). Combining CA125 (>40 U/mL) and N-terminal pro B-type natriuretic peptide (NT-proBNP) (>2500 pg/mL) significantly improved the diagnostic accuracy of the model. Patients with both biomarkers above their respective cut-offs had a three-fold higher likelihood of ATTR-CA (odds ratio: 3.38; 1.704–6.719; P < .001).

Conclusions

In ambulatory patients with suspected ATTR-CA, a CA125 > 40 U/mL, particularly when combined with elevated NT-proBNP, supports the clinical suspicion of the disease. High CA125 levels may be useful in ATTR-CA recognition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CA-125 AntigenAmyloid Neuropathies, FamilialCardiomyopathiesHumansRetrospective StudiesMaleFemaleBiomarkersAgedCase-Control Studies

Stichwörter der Autor:innen

CA125Heart failureTransthyretin cardiac amyloidosis

Substanzen

CA-125 AntigenBiomarkers

Autor:innen und Institutionen

  • Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain.
  • Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
  • Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, 46010 Valencia, Spain.
  • Universitat de Valencia, 46010 Valencia, Spain.
  • Department of Cardiology, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
  • Departamento de Medicina, Universidad Autónoma de Barcelona, 08193 Barcelona, Spain.

ORCID-Profile: Belén Peiró-Aventín, Rafael de la Espriella, Julio Núñez

Förderung

  • Instituto de Salud Carlos III
  • European Regional Development Fund/European Social Fund
  • Fundacion Eugenio Rodriguez Pascual
  • Pfizer
  • MCIN
  • Pro-CNIC Foundation
  • Severo Ochoa Centers of Excellence programme

Zitieren

APA

Peiró-Aventín, B., Santas, E., Ruiz-Cueto, M., Mora-Ayestarán, N., Briceño, A., Badia, C., de Castro, D., de la Espriella, R., Angulo-Lara, B., Espinoza, A., García, J. F., Rada, M. M., Vidal, I. S., Domínguez, F., González-López, E., Bayés-Genís, A., Garcia-Pavia, P., & Núñez, J. (2026). High CA125 levels as a red flag for ATTR cardiac amyloidosis. ESC Heart Failure, 13(4). https://doi.org/10.1093/eschf/xvag199

Vancouver

Peiró-Aventín B, Santas E, Ruiz-Cueto M, Mora-Ayestarán N, Briceño A, Badia C, et al. High CA125 levels as a red flag for ATTR cardiac amyloidosis. ESC Heart Failure. 2026;13(4). doi:10.1093/eschf/xvag199

BibTeX
@article{PeirAventn2026,
  author = {Peiró-Aventín, Belén and Santas, Enrique and Ruiz-Cueto, María and Mora-Ayestarán, Nerea and Briceño, Ana and Badia, Clara and de Castro, Daniel and de la Espriella, Rafael and Angulo-Lara, Basilio and Espinoza, Ana and García, Jorge De La Fuente and Rada, Mikel Maeztu and Vidal, Ignasi Segarra and Domínguez, Fernando and González-López, Esther and Bayés-Genís, Antoni and Garcia-Pavia, Pablo and Núñez, Julio},
  title = {High CA125 levels as a red flag for ATTR cardiac amyloidosis},
  journal = {ESC Heart Failure},
  year = {2026},
  volume = {13},
  number = {4},
  doi = {10.1093/eschf/xvag199}
}
Kostenlos starten →